A post hoc analysis was used in a multicenter cohort study on 3808 COVID-19 hospitalized patients to assess the effectiveness of early intramuscular IFN-β administration and its impact on the death rate after 30 days [112]. The gene discussed is IFNB1; the disease is COVID-19.